NY-IFF
10.2.2020 22:17:12 CET | Business Wire | Press release
Regulatory News:
IFF (NYSE: IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent and nutrition, today announced its third consecutive recognition on Barron’s 100 Most Sustainable Companies List, an index first launched in February 2018. It joins the ranks of 99 other leading U.S. companies assessed for environmental, social and corporate governance practices.
“We are delighted to once again be named to Barron’s prestigious sustainability index,” said Andreas Fibig, IFF Chairman & CEO. “This recognition is further testament to our passionate employees across the world and IFF’s commitment to global sustainability leadership, as we redefine how we live in and care for the resources of our world.”
In partnership with U.S. based investment advisory firm Calvert Research and Management, the Barron’s list was compiled by evaluating the 1000 largest publicly traded companies against hundreds of ESG performance indicators. These indicators, which address topics such as workplace diversity, data security and greenhouse-gas emissions, were then used to rank each company’s performance in five key constituencies: shareholders, employees, customers, community and the planet.
IFF’s EVP, Chief Global Scientific & Sustainability Officer Dr. Gregory Yep said, “This is a fantastic achievement for IFF, where sustainability priorities remain deeply connected to the overall success of our organization. As IFF continues to grow and evolve, we remain focused on opportunities to create a smarter, greener and more viable company positioned to protect our planet and the well-being of future generations.”
Through 2019, the Company:
- Continues to execute on its environmental goals focused on emission reductions, zero waste to landfill and water stewardship, known collectively as “EcoEffective+”
- Signed the United Nations’ “Business Ambition for 1.5°C – Our Only Future” pledge, a campaign to put more aggressive science-based goals into action to help limit global temperature rise to 1.5 degrees Celsius
- Received Double-A distinction from CDP, including recognition on CDP’s A List for Climate Change (fifth consecutive) and Water Security (second consecutive), reaffirming IFF’s global leadership in environmental responsibility
- Opened the industry’s largest solar array at its Union Beach, New Jersey property, which is expected to generate over nine million kilowatt hours annually, powering IFF’s R&D facility and returning any excess energy to the grid
- Deepened its commitment to diversity and inclusion by signing onto the United Nations Global LGBTI Standards of Conduct for Business (“the Standards”), joining 250 of the world’s largest companies in the pledge to tackle discrimination against lesbian, gay, bisexual, transsexual and intersex (LGBTI) people in the community, workplace and marketplace
- Solidified its commitment to gender parity and women’s empowerment by pledging to adopt the United Nations Women’s Empowerment Principles (“the Principles”), a set of seven tenets to advance and empower women and provide equal treatment in the workplace, marketplace and community
- Received the 2019 “Industry Mover” award from SAM, a subsidiary of RobecoSAM which specializes in providing ESG data, benchmarks and ratings, for the Company’s top-scoring performance in economic, social and environmental categories
- Pledged to achieve a full global EDGE certification in 2020, to advance the Company’s certification from the Economic Dividends for Gender Equality (EDGE) for its business in the United States
- Installed a series of nesting platforms to support the conservation of ospreys, a North American raptor species challenged by environmental changes
For more information on sustainability at IFF, visit https://www.iff.com/en/our-purpose/sustainability .
# # #
Welcome to IFF
At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200210005758/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
